Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocuphire Pharma Inc
(NQ:
OCUP
)
1.260
+0.040 (+3.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocuphire Pharma Inc
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 08, 2021
Gainers Aethlon Medical (NASDAQ:AEMD) sto...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
June 03, 2021
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
April 22, 2021
Gainers Ocugen (NASDAQ:OCGN) stock moved upwards by 7.1% to $9.95 during Thursday's after-market session. At the close, Ocugen's trading volume reached 7.6 million shares...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
April 19, 2021
During Monday's morning trading, 29 companies set new 52-week lows. Intriguing Points: Ascendis Pharma (NASDAQ:ASND) is the largest company in terms of market...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
April 16, 2021
Before 10 a.m. ET Friday, 62 stocks made new 52-week lows. Significant Points: The largest company by market cap to set a new 52-week low was Yatsen Holding (NYSE:...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 13, 2021
Tuesday morning, 38 companies set new 52-week lows. Key Facts: Viatris (NASDAQ:VTRS) was the largest company by market cap to set a new 52-week low. Enservco (AMEX:...
Via
Benzinga
Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
April 08, 2021
Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.